If I understand you, you are arguing the very opposite
Yeah that's right. All things being equal, DCC's market value should rise relative to the pre-tender announcement price by the amount of shares outstanding that get taken out, adjusted for the earnings no longer owned by the business. Some of that move has already occurred because the market efficiently prices in the probability of a successful tender.
What you are describing, a share price that falls back to ~£49.60, would effectively signal a failed tender. It would imply the market believes DCC destroyed value by selling a unit and buying back stock.
Broadly, a drop back to that price means the market believes DCC first didn't get a good price for Healthcare, and then misspent the proceeds buying back £600m of its own shares in a 'worse' business (Energy).
In reality, the math proves the opposite. They sold a low-growth asset (Healthcare) at a high multiple to double down on a higher-growth, higher-RoE asset (themselves) at a low multiple.
Here is the actual math on the trade:
1. The 'Sell High' (DCC Healthcare Disposal)
- Sale Price: Sold for an Enterprise Value of £1.05 billion.
- Earnings Lost: In FY24, Healthcare contributed ~£88.1m (12.9% of group operating profit).
- The Multiple: They sold the division at roughly 12x Operating Profit.
- The Pot: They are using £600m of proceeds for this tender.
- The Strike: At the mid-point (£51.70), they will cancel ~11.6 million shares.
- The Multiple: At £51.70, DCC trades at roughly 10x earnings (and closer to 7x EV/EBITDA).
If the share price falls back to £49.60 after the tender, the market would be assigning a P/E of roughly 9x to the remaining business. This would be a perverse outcome: punishing the company for a value-accretive deal.
The Financial Engineering Trick. The real magic here is how they protected EPS while shrinking the company.
- Operating Profit Lost: DCC gave away 12.9% of its operating profit (Healthcare).
- Share Count Reduced: Between the £100m buyback already done (~2.8% reduction), the current tender (~11.8% reduction), and the future £100m earn-out (~2% reduction), they are on track to shrink the share count by ~16.6%.